The legal complaint alleges that Erasca misled investors regarding the development of its ERAS-0015 drug candidate. According to the filing, the company allegedly relied on improper preclinical comparisons to RevMed, creating significant risks related to patent and trade secret protections. The suit contends that these omissions rendered the company's public statements regarding its business operations materially misleading.

Investors who purchased securities during this window are not required to take immediate action to remain part of the potential class, as no class has yet been certified. Those interested in pursuing the role of lead plaintiff must file their motion by the August 10, 2026, deadline. Legal counsel representing the action can be reached at 310-201-9150 for further information regarding individual rights and the recovery process.